ArticleAmerican journal of cancer research2026
Transcriptional regulation of ubiquitin specific peptidase 2b by farnesoid X receptor and its implications in the pathogenesis of hepatocellular carcinoma.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Farnesoid X receptor (FXR) signaling plays an important role in liver regeneration and carcinogenesis. Dysregulation of FXR signaling is linked to the pathogenesis of hepatocellular carcinoma (HCC) while FXR knockout mice spontaneously develop HCC as they age. Ubiquitin specific peptidase 2b (USP2b) is a deubiquitinating enzyme regulating protein stability and other activities. In our recent study, we found that USP2b was significantly downregulated in subjects with HCC and exhibited both tumor-promoting and tumor suppressive activity in a context-dependent manner. However, the mechanistic link between FXR signaling and USP2b and its implications in the pathogenesis of HCC remain to be determined. In this study, we revealed that USP2b was transcriptionally regulated by FXR. Activation of FXR significantly increased while antagonizing FXR reduced USP2b mRNA and protein expression
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.